查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007879

微生物组疗法市场预测至2034年—按产品类型、给药途径、技术、应用、最终用户和地区分類的全球分析

Microbiome Therapeutics Market Forecasts to 2034 - Global Analysis By Product Type, Route of Administration, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球微生物组疗法市场将达到 96 亿美元，并在预测期内以 15.8% 的复合年增长率增长，到 2034 年达到 312 亿美元。

微生物组疗法是指透过调节人体微生物组的组成和功能来预防、治疗或控制疾病的生物干预措施。人体微生物组是由多种微生物组成的复杂群落，栖息于肠道、皮肤、呼吸道以及身体其他部位。这些治疗方法包括生物製药产品、益生菌、益生元、合益素、粪便微生物移植。它们透过恢復微生物组生态系的平衡，来治疗发炎性肠道疾病、困难梭状桿菌感染疾病、代谢紊乱、肿瘤以及神经精神疾病。

肠道疾病盛行率增加

发炎性肠道疾病、大肠激躁症和困难梭状桿菌感染疾病在全球范围内的日益流行，是推动製药企业投资以微生物组为基础的治疗方案的主要动力。儘管传统的抗生素和免疫抑制疗法有其局限性，仍无法满足所有患者的需求，但基于微生物组的疗法有望透过改变疾病进程而非仅仅抑制症状来满足这些需求。美国食品药物管理局（FDA）对生物治疗产品的核准框架日益成熟，加速了商业化研发管线的投资，并推动了针对主要消化器官系统和全身性疾病适应症的后期临床试验计画。

製造业标准化的复杂性

生产标准化的复杂性构成了一项重大障碍。这是因为生物製药和粪便微生物移植需要不同批次产品中微生物群落组成的一致性。目前的GMP框架和品管检测体系仍在发展完善，以应对此一挑战。在生产、製剂和低温运输配送过程中保持菌株活性，显着增加了操作的复杂性。美国、欧洲和亚太地区在生物製药产品分类方面的监管差异，造成了并行的申请负担，对小规模的微生物治疗研发公司造成了不成比例的影响。

肿瘤学中的微生物组调控

随着越来越多的临床证据显示肠道菌丛的组成显着影响癌症免疫疗法的反应率和毒性特征，肿瘤学领域的菌丛调控展现出突破性的商业性机会。旨在优化抗肿瘤免疫反应并与查核点抑制剂合併使用的生物治疗产品已展现出令人瞩目的早期临床数据。製药公司正与菌丛平台开发商进行策略合作，将菌丛调控纳入黑色素瘤、肺癌和其他固体癌的癌症免疫通讯协定中，使其成为标准组成部分。

益生菌消费品竞争产品

来自消费级益生菌产品的价格竞争给临床级微生物组疗法带来了报销和市场定位的挑战。这是因为医生和患者可能认为市售益生菌补充剂与处方笺具有同等疗效，但价格却低得多。要将临床级微生物组疗法与普通保健产品区分开来，需要持续进行医生教育，并提供强有力的对比临床试验证据。监管机构在区分食品级和药品级微生物组干预措施方面也面临定义上的挑战，这造成了合规性方面的模糊不清，并使市场定位变得更加复杂。

新冠疫情的影响：

针对新冠病毒的研究揭示了肠道菌群紊乱与新冠病毒感染的严重程度以及长期新冠症状的持续存在之间存在显着关联，这极大地提升了科学界和投资者对基于微生物组的治疗性介入的兴趣。疫情期间开展的旨在评估微生物组调控以增强呼吸道感染疾病抵抗力的研究项目，拓展了治疗应用范围。疫情后对微生物组研究的投资以及监管力道的加大，缩短了关键生物医学候选产品的研发週期。

在预测期内，生物医学产品（LBP）细分市场预计将占据最大的市场份额。

预计在预测期内，生物製药（LBP）领域将占据最大的市场份额。这是因为FDA和EMA已将生物製药认定为具有明确监管路径的独特药物类别，从而能够进行有价值的临床开发项目。目前，针对艰难梭菌感染疾病、发炎性肠道疾病和肿瘤适应症的多个LBP候选药物正处于II期和III期临床试验阶段。与普通益生菌相比，生物製药具有明显的临床差异，且医保报销前景良好，这些因素正吸引製药业持续投资该领域。

在预测期内，口腔市场预计将呈现最高的复合年增长率。

在预测期内，口服製剂市场预计将呈现最高的成长率。这主要得益于患者对非侵入性给药方式的偏好，以及製药业对新一代包封技术的投资，这些技术能够保护活性微生物製剂免受胃酸降解。口服给药方式使得门诊病人可以自行给药，显着扩大了目标患者群体，使其不再局限于医院进行的粪便微生物移植（FMT）手术。肠溶衣技术和产孢微生物製剂的进步正在改善口服活性微生物製剂的临床疗效，并有助于与监管机构更好地合作，从而支持产品核可。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额，这主要得益于美国食品药物管理局 (FDA) 在建立生物医学产品核准框架方面的监管主导地位、微生物组生物技术公司的集中以及该领域的大量创业投资投资。美国拥有全球最高的处于临床阶段的微生物组治疗项目密度。胃肠道疾病的高发生率、完善的专科药物报销体係以及领先的微生物组学术研究机构的存在，共同支撑了北美商业生态系统的主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于中国、日本和韩国生物技术投资的不断增长、人们对肠道健康疗法的日益关注，以及大量胃肠道疾病患者。亚太地区各国政府资助的微生物组研究倡议正在建构临床试验基础设施和监管合规能力，吸引国际製药公司合作。由于益生菌和发酵食品在当地文化中根深蒂固，消费者对基于微生物组的治疗理念接受度较高，这加速了处方药的普及。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

第二章：引言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 促进因素
  • 抑制因子
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章：波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的竞争

第五章 全球微生物组疗法市场：依产品类型划分

  • 益生菌类治疗药物
    • 单菌株益生菌
    • 多菌株益生菌
    • 新一代益生菌
  • 益生元疗法
    • 寡糖
    • 膳食纤维
  • 合益素
  • 粪便微生物移植（FMT）
  • 生物医学产品（LBPs）

第六章：全球微生物组疗法市场：依给药途径划分

  • 口服
  • 直肠
  • 局部的
  • 其他的

第七章 全球微生物组疗法市场：依技术划分

  • 微生物组定序技术
  • 总体基因体学和生物资讯学
  • 微生物基因工程
  • 药物传输技术
  • 人工智慧驱动的微生物组分析

第八章 全球微生物组疗法市场：依应用划分

  • 消化系统疾病
    • 发炎性肠道疾病（IBD）
    • 大肠激躁症（IBS）
  • 代谢性疾病
    • 肥胖
    • 糖尿病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学

第九章：全球微生物组疗法市场：依最终用户划分

  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构
  • 受託研究机构
  • 其他最终用户

第十章 全球微生物组疗法市场：依地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 主要发展

  • 合约、伙伴关係、合作关係、合资企业
  • 收购与併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章：公司简介

  • Seres Therapeutics
  • Ferring Pharmaceuticals
  • Enterome
  • Second Genome
  • Rebiotix
  • 4D Pharma
  • Vedanta Biosciences
  • Synlogic
  • BiomeBank
  • Yakult Honsha
  • Nestle Health Science
  • Danone
  • DuPont（IFF）
  • Probi AB
  • Chr. Hansen
  • Novozymes
  • Optibiotix Health
  • Evelo Biosciences
Product Code: SMRC34769

According to Stratistics MRC, the Global Microbiome Therapeutics Market is accounted for $9.6 billion in 2026 and is expected to reach $31.2 billion by 2034 growing at a CAGR of 15.8% during the forecast period. Microbiome therapeutics refer to biological interventions designed to modulate the composition and function of the human microbiome the complex community of microorganisms inhabiting the gut, skin, respiratory tract, and other body sites to prevent, treat, or manage disease conditions. They encompass live biotherapeutic products, probiotics, prebiotics, synbiotics, and fecal microbiota transplantation formulations. These therapeutics target inflammatory bowel disease, Clostridioides difficile infections, metabolic disorders, oncology indications, and neuropsychiatric conditions by restoring dysbiotic microbial ecosystems.

Market Dynamics:

Driver:

Rising Gut Disorder Prevalence

Rising global prevalence of inflammatory bowel disease, irritable bowel syndrome, and Clostridioides difficile infections is a primary driver compelling pharmaceutical investment in microbiome therapeutic solutions. Conventional antibiotic and immunosuppressive treatment limitations create unmet clinical needs that microbiome-based interventions are positioned to address with disease-modifying rather than symptom-suppressing mechanisms. FDA approval frameworks for live biotherapeutic products are maturing, accelerating commercial pipeline investment and generating late-stage clinical programs across major gastrointestinal and systemic disease indications.

Restraint:

Manufacturing Standardization Complexity

Manufacturing standardization complexity represents a critical barrier as live biotherapeutic products and fecal microbiota transplantation formulations require consistent microbial community composition across production batches - a challenge that current GMP frameworks and quality control assay infrastructure are still evolving to address. Strain viability maintenance during manufacturing, formulation, and cold-chain distribution imposes substantial operational complexity. Regulatory divergence between the United States, Europe, and Asia Pacific on live biotherapeutic product classification creates parallel submission burdens that disproportionately impact smaller microbiome therapeutic developers.

Opportunity:

Oncology Microbiome Modulation

Oncology microbiome modulation presents a transformative commercial opportunity as clinical evidence accumulates demonstrating that gut microbiome composition significantly influences cancer immunotherapy response rates and treatment toxicity profiles. Live biotherapeutic products designed to optimize anti-tumor immune responses in combination with checkpoint inhibitor regimens are generating compelling early clinical data. Pharmaceutical companies are forming strategic partnerships with microbiome platform developers to incorporate microbiome modulation as a standard component of cancer immunotherapy protocols across melanoma, lung cancer, and other solid tumor indications.

Threat:

Competitive Probiotic Consumer Products

Competitive pricing pressure from consumer probiotic products creates a reimbursement and positioning challenge for clinical microbiome therapeutics, as physicians and patients may perceive commercial probiotic supplements as equivalent alternatives to prescription-grade live biotherapeutic products at substantially lower cost. Differentiating clinical-grade microbiome therapeutics from consumer wellness products requires sustained physician education investment and robust comparative clinical trial evidence. Regulatory agencies face definitional challenges distinguishing food-grade from drug-grade microbiome interventions, creating compliance ambiguity that complicates market positioning.

Covid-19 Impact:

COVID-19 research identified significant associations between gut microbiome dysbiosis and COVID-19 disease severity and long-COVID symptom persistence, generating substantial scientific and investor interest in microbiome therapeutic interventions. Pandemic-era research programs evaluating microbiome modulation for respiratory infection resilience have expanded the recognized therapeutic application scope. Post-pandemic, accelerated microbiome research investment and regulatory agency engagement have shortened development timelines for leading live biotherapeutic product candidates.

The live biotherapeutic products (LBPs) segment is expected to be the largest during the forecast period

The live biotherapeutic products (LBPs) segment is expected to account for the largest market share during the forecast period, due to FDA and EMA recognition of LBPs as a distinct pharmaceutical category with defined regulatory pathways, enabling investment-grade clinical development programs. Multiple LBP candidates addressing C. difficile infection, inflammatory bowel disease, and oncology indications are in Phase II and Phase III clinical stages. Strong clinical evidence differentiation from general probiotics and clear reimbursement pathway visibility are attracting sustained pharmaceutical industry investment in the segment.

The oral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oral segment is predicted to witness the highest growth rate, driven by patient preference for non-invasive delivery formats and pharmaceutical investment in next-generation encapsulation technologies that protect live microbiome formulations from gastric acid degradation. Oral delivery enables outpatient self-administration, substantially expanding addressable patient populations beyond hospital-administered fecal microbiota transplantation procedures. Advancements in enteric coating technologies and spore-forming organism formulations are improving oral LBP clinical performance, generating positive regulatory interactions supporting product approvals.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to FDA regulatory leadership in establishing live biotherapeutic product approval frameworks, concentration of microbiome biotechnology companies, and substantial venture capital investment in the sector. The United States hosts the highest density of clinical-stage microbiome therapeutic programs globally. High gastrointestinal disease prevalence, well-developed specialty pharmaceutical reimbursement infrastructure, and leading academic microbiome research institutions sustain North America's commercial ecosystem dominance.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to expanding biotechnology investment in China, Japan, and South Korea, growing awareness of gut health therapeutics, and large patient populations with gastrointestinal disorders. Government-funded microbiome research initiatives across Asia Pacific are building clinical trial infrastructure and regulatory competency that are attracting international pharmaceutical partnerships. Cultural integration of probiotic and fermented food traditions creates consumer openness to microbiome-based therapeutic concepts that accelerates prescription adoption.

Key players in the market

Some of the key players in Microbiome Therapeutics Market include Seres Therapeutics, Ferring Pharmaceuticals, Enterome, Second Genome, Rebiotix, 4D Pharma, Vedanta Biosciences, Synlogic, BiomeBank, Yakult Honsha, Nestle Health Science, Danone, DuPont (IFF), Probi AB, Chr. Hansen, Novozymes, Optibiotix Health, and Evelo Biosciences.

Key Developments:

In March 2026, Seres Therapeutics initiated a Phase II combination study evaluating its microbiome therapeutic alongside pembrolizumab for solid tumor indications including non-small cell lung cancer.

In February 2026, Synlogic advanced its engineered probiotic candidate for phenylketonuria into Phase III pivotal trials following positive interim metabolic control endpoint data.

In January 2026, Ferring Pharmaceuticals received expanded FDA approval for its live biotherapeutic product REBYOTA covering additional C. difficile recurrence prevention indications in immunocompromised patients.

In November 2025, Vedanta Biosciences reported positive Phase II efficacy data for its defined bacterial consortium LBP targeting ulcerative colitis remission induction in moderate-to-severe patients.

Product Types Covered:

  • Probiotics-based Therapeutics
  • Prebiotics-based Therapeutics
  • Synbiotics
  • Fecal Microbiota Transplantation (FMT)
  • Live Biotherapeutic Products (LBPs)

Route of Administrations Covered:

  • Oral
  • Rectal
  • Topical
  • Others

Technologies Covered:

  • Microbiome Sequencing Technologies
  • Metagenomics & Bioinformatics
  • Genetic Engineering of Microbes
  • Drug Delivery Technologies
  • AI-driven Microbiome Analysis

Applications Covered:

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Oncology

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Other End Userz

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microbiome Therapeutics Market, By Product Type

  • 5.1 Probiotics-based Therapeutics
    • 5.1.1 Single-Strain Probiotics
    • 5.1.2 Multi-Strain Probiotics
    • 5.1.3 Next-Generation Probiotics
  • 5.2 Prebiotics-based Therapeutics
    • 5.2.1 Oligosaccharides
    • 5.2.2 Dietary Fibers
  • 5.3 Synbiotics
  • 5.4 Fecal Microbiota Transplantation (FMT)
  • 5.5 Live Biotherapeutic Products (LBPs)

6 Global Microbiome Therapeutics Market, By Route of Administration

  • 6.1 Oral
  • 6.2 Rectal
  • 6.3 Topical
  • 6.4 Others

7 Global Microbiome Therapeutics Market, By Technology

  • 7.1 Microbiome Sequencing Technologies
  • 7.2 Metagenomics & Bioinformatics
  • 7.3 Genetic Engineering of Microbes
  • 7.4 Drug Delivery Technologies
  • 7.5 AI-driven Microbiome Analysis

8 Global Microbiome Therapeutics Market, By Application

  • 8.1 Gastrointestinal Disorders
    • 8.1.1 Inflammatory Bowel Disease (IBD)
    • 8.1.2 Irritable Bowel Syndrome (IBS)
  • 8.2 Metabolic Disorders
    • 8.2.1 Obesity
    • 8.2.2 Diabetes
  • 8.3 Infectious Diseases
  • 8.4 Neurological Disorders
  • 8.5 Oncology

9 Global Microbiome Therapeutics Market, By End User

  • 9.1 Hospitals & Clinics
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Research Institutes
  • 9.4 Contract Research Organizations
  • 9.5 Other End Userz

10 Global Microbiome Therapeutics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Seres Therapeutics
  • 12.2 Ferring Pharmaceuticals
  • 12.3 Enterome
  • 12.4 Second Genome
  • 12.5 Rebiotix
  • 12.6 4D Pharma
  • 12.7 Vedanta Biosciences
  • 12.8 Synlogic
  • 12.9 BiomeBank
  • 12.10 Yakult Honsha
  • 12.11 Nestle Health Science
  • 12.12 Danone
  • 12.13 DuPont (IFF)
  • 12.14 Probi AB
  • 12.15 Chr. Hansen
  • 12.16 Novozymes
  • 12.17 Optibiotix Health
  • 12.18 Evelo Biosciences

List of Tables

  • Table 1 Global Microbiome Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Microbiome Therapeutics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Microbiome Therapeutics Market Outlook, By Probiotics-based Therapeutics (2023-2034) ($MN)
  • Table 4 Global Microbiome Therapeutics Market Outlook, By Single-Strain Probiotics (2023-2034) ($MN)
  • Table 5 Global Microbiome Therapeutics Market Outlook, By Multi-Strain Probiotics (2023-2034) ($MN)
  • Table 6 Global Microbiome Therapeutics Market Outlook, By Next-Generation Probiotics (2023-2034) ($MN)
  • Table 7 Global Microbiome Therapeutics Market Outlook, By Prebiotics-based Therapeutics (2023-2034) ($MN)
  • Table 8 Global Microbiome Therapeutics Market Outlook, By Oligosaccharides (2023-2034) ($MN)
  • Table 9 Global Microbiome Therapeutics Market Outlook, By Dietary Fibers (2023-2034) ($MN)
  • Table 10 Global Microbiome Therapeutics Market Outlook, By Synbiotics (2023-2034) ($MN)
  • Table 11 Global Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplantation (FMT) (2023-2034) ($MN)
  • Table 12 Global Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (LBPs) (2023-2034) ($MN)
  • Table 13 Global Microbiome Therapeutics Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 14 Global Microbiome Therapeutics Market Outlook, By Oral (2023-2034) ($MN)
  • Table 15 Global Microbiome Therapeutics Market Outlook, By Rectal (2023-2034) ($MN)
  • Table 16 Global Microbiome Therapeutics Market Outlook, By Topical (2023-2034) ($MN)
  • Table 17 Global Microbiome Therapeutics Market Outlook, By Others (2023-2034) ($MN)
  • Table 18 Global Microbiome Therapeutics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 19 Global Microbiome Therapeutics Market Outlook, By Microbiome Sequencing Technologies (2023-2034) ($MN)
  • Table 20 Global Microbiome Therapeutics Market Outlook, By Metagenomics & Bioinformatics (2023-2034) ($MN)
  • Table 21 Global Microbiome Therapeutics Market Outlook, By Genetic Engineering of Microbes (2023-2034) ($MN)
  • Table 22 Global Microbiome Therapeutics Market Outlook, By Drug Delivery Technologies (2023-2034) ($MN)
  • Table 23 Global Microbiome Therapeutics Market Outlook, By AI-driven Microbiome Analysis (2023-2034) ($MN)
  • Table 24 Global Microbiome Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 25 Global Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 26 Global Microbiome Therapeutics Market Outlook, By Inflammatory Bowel Disease (IBD) (2023-2034) ($MN)
  • Table 27 Global Microbiome Therapeutics Market Outlook, By Irritable Bowel Syndrome (IBS) (2023-2034) ($MN)
  • Table 28 Global Microbiome Therapeutics Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 29 Global Microbiome Therapeutics Market Outlook, By Obesity (2023-2034) ($MN)
  • Table 30 Global Microbiome Therapeutics Market Outlook, By Diabetes (2023-2034) ($MN)
  • Table 31 Global Microbiome Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 32 Global Microbiome Therapeutics Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 33 Global Microbiome Therapeutics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 34 Global Microbiome Therapeutics Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 Global Microbiome Therapeutics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 36 Global Microbiome Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 37 Global Microbiome Therapeutics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 38 Global Microbiome Therapeutics Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 39 Global Microbiome Therapeutics Market Outlook, By Other End Userz (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.